Rosuvastatin
- Generic Name
- Rosuvastatin
- Brand Names
- Crestor, Ezallor, Roszet
- Drug Type
- Small Molecule
- Chemical Formula
- C22H28FN3O6S
- CAS Number
- 287714-41-4
- Unique Ingredient Identifier
- 413KH5ZJ73
- Background
Rosuvastatin, also known as the brand name product Crestor, is a lipid-lowering drug that belongs to the statin class of medications, which are used to lower the risk of cardiovascular disease and manage elevated lipid levels by inhibiting the endogenous production of cholesterol in the liver. More specifically, statin medications competitively inhibit the e...
- Indication
The FDA monograph states that rosuvastatin is indicated as an adjunct to diet in the treatment of triglyceridemia, Primary Dysbetalipoproteinemia (Type III Hyperlipoproteinemia), and Homozygous Familial Hypercholesterolemia.
...
- Associated Conditions
- Atherosclerosis, Atherosclerotic Cardiovascular Diseases, Cardiovascular Disease (CVD), Cardiovascular Events, Dysbetalipoproteinemia, Heterozygous Familial Hypercholesterolemia (HeFH), High Cholesterol, Homozygous Familial Hypercholesterolaemia (HoFH), Hypertension, Hypertension, Essential Hypertension, Hypertriglyceridemias, Major Adverse Cardiovascular Events, Mixed Dyslipidemias, Postoperative Thromboembolism, Primary Hypercholesterolemia, Primary Hyperlipidemia
- Associated Therapies
- Lipid-Lowering Therapy, Primary Prevention of Cardiovascular Diseases
Study of Asian Patients With Hypercholesterolaemia in the UK - Rosuvastatin 5mg Versus Atorvastatin 10mg
- Conditions
- Interventions
- First Posted Date
- 2007-01-29
- Last Posted Date
- 2010-12-16
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 55
- Registration Number
- NCT00427960
- Locations
- 🇬🇧
Research Site, Newcastle, United Kingdom
🇬🇧Research SIte, Slough, United Kingdom
ORBITAL: Open-Label Primary Care Study: Rosuvastatin Based Compliance Initiatives Linked To Achievement Of LDL Goals
- Conditions
- First Posted Date
- 2006-11-06
- Last Posted Date
- 2009-03-26
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1294
- Registration Number
- NCT00396240
ROMEO (Rosuvastatin in Metabolic syndrOme)
- First Posted Date
- 2006-11-03
- Last Posted Date
- 2011-07-11
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 258
- Registration Number
- NCT00395486
- Locations
- 🇰🇷
Research Site, Suwon, Korea, Republic of
Rosuvastatin ORBITAL Germany
- Conditions
- First Posted Date
- 2006-09-21
- Last Posted Date
- 2009-03-26
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 8000
- Registration Number
- NCT00379249
Aspirin and Statins for Prevention of Atherosclerosis and Arterial Thromboembolism in Systemic Lupus Erythematosus
- Conditions
- Interventions
- First Posted Date
- 2006-09-04
- Last Posted Date
- 2010-09-16
- Lead Sponsor
- Tuen Mun Hospital
- Target Recruit Count
- 72
- Registration Number
- NCT00371501
- Locations
- 🇭🇰
Tuen Mun Hospital, Hong Kong, Hong Kong
Rosuvastatin for Hepatitis C
- Conditions
- First Posted Date
- 2006-09-04
- Last Posted Date
- 2015-06-03
- Lead Sponsor
- UMC Utrecht
- Registration Number
- NCT00371579
- Locations
- 🇳🇱
University Medical Center Utrecht, Utrecht, Netherlands
Effect of Rosuvastatin in Intracerebral Hemorrhage
- First Posted Date
- 2006-08-15
- Last Posted Date
- 2009-03-26
- Lead Sponsor
- Universidad Autonoma de San Luis Potosí
- Target Recruit Count
- 75
- Registration Number
- NCT00364559
- Locations
- 🇲🇽
Hospital Central "Dr. Ignacio Morones Prieto", San Luis Potosi, Mexico
Effect of Rosuvastatin in Abdominal Sepsis
- Conditions
- First Posted Date
- 2006-07-27
- Last Posted Date
- 2011-02-21
- Lead Sponsor
- Universidad Autonoma de San Luis Potosí
- Target Recruit Count
- 60
- Registration Number
- NCT00357123
- Locations
- 🇲🇽
Hospital Central "Dr. Ignacio Morones Prieto, San Luis Potosi, Mexico
PLUTO: Pediatric Lipid-redUction Trial of rOsuvastatin
- First Posted Date
- 2006-07-24
- Last Posted Date
- 2011-08-31
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 173
- Registration Number
- NCT00355615
- Locations
- 🇪🇸
Research Site, Reus, Spain
🇳🇱Research SIte, Waalwijk, Netherlands
Pharmacokinetic (PK) Study of Single-dose Rosuvastatin and Tipranavir/Ritonavir in Healthy Subjects
- First Posted Date
- 2006-06-26
- Last Posted Date
- 2016-02-04
- Lead Sponsor
- Johns Hopkins University
- Target Recruit Count
- 29
- Registration Number
- NCT00344123
- Locations
- 🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.